Clinical trial
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
NCT00404326 · National Institute of Cancerología, Other · Completed
Key facts
| NCT number | NCT00404326 |
|---|---|
| Title | Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer |
| Official title | A Phase II Study of Transcriptional Therapy With the DNA Demethylating Hydralazine and the HDAC Inhibitor Valproate Associated to Concomitant Cisplatin Chemoradiation in FIGO Stage III Cervical Cancer. |
| Lead sponsor | National Institute of Cancerología, Other |
| Collaborators | National Council of Science and Technology, Mexico Psicofarma, S.A. De C.V. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Hydralazine and magnesium valproate, Punch biopsy of the primary tumor |
| Enrollment | 18 |
| Start date | May 1, 2005 |
| Completion | Nov 1, 2006 |
| First posted | Nov 28, 2006 |
| Last update posted | Nov 28, 2006 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: